What’s new in lipid management for those with elevated lipoprotein(a) levels ≥60 mg/dL or 120 nmol/L?

Our host, Dr. George Thanassoulis, takes a deeper look into this topic with Dr. Priya Manjoo, an Endocrinologist and Certified Specialist in both Hypertension and Obesity Medicine at the Victoria Cardiometabolic Collaborative Clinic, and a Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia’s Faculty of Medicine.

This episode discusses how the recently updated Canadian Cardiovascular Society Guidelines have changed the clinical practice of lipid management in patients with high lipoprotein(a) levels (≥60 mg/dL or 120 nmol/L). Our experts take a deeper dive into recent advances in the understanding of lipoprotein(a) as a risk factor for atherosclerotic disease, and the importance of identifying these high-risk patients. They also discuss how this patient subgroup may benefit from use of more intensive therapies, such as PCSK9 inhibitors, to achieve further LDL cholesterol lowering and reduce the risk of future cardiovascular events and complications.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr.  Thanassoulis:

• Direct financial relationship including receipt of honoraria: Sanofi. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, Novartis, Silence.

Dr. Manjoo:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Bosch health, HLS therapeutics. Membership on advisory boards or speaker’s bureau: Novo Nordisk, Bosch health. Lilly, Amgen bone health.